<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525119</url>
  </required_header>
  <id_info>
    <org_study_id>DEN-314</org_study_id>
    <secondary_id>2017-001071-23</secondary_id>
    <secondary_id>U1111-1192-7761</secondary_id>
    <secondary_id>18/NW/0008</secondary_id>
    <nct_id>NCT03525119</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine</brief_title>
  <official_title>A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) Vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Country(Ies) for Dengue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the immunogenicity and safety of the concomitant
      administration of TDV (subcutaneous [SC] injection) and of hepatitis A virus (HAV) vaccine
      (intramuscular [IM] injection) in healthy participants aged 18 to 60 years living in
      country(ies) non-endemic for both dengue and hepatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine tested in this study is TDV. TDV co-administered with HAV vaccine will be tested
      to assess immunogenicity and safety in healthy participants in non-endemic area(s) for dengue
      and HAV.

      The study will enroll approximately 900 patients. Participants will be randomly assigned to
      one of the three groups—which will remain undisclosed to the observer. Participants will be
      randomized in 1:1:1 ratio to receive:

        -  Group 1: HAV vaccine (IM) and TDV placebo-matching injection (SC), co-administered at
           Day 1 (Month 0 [M0]); TDV placebo-matching injection (SC) administered at Day 90 (Month
           3 [M3])

        -  Group 2: TDV (SC) and HAV placebo-matching injection (IM), co-administered at Day 1
           (Month 0 [M0]); TDV (SC) administered at Day 90(Month 3 [M3])

        -  Group 3: TDV (SC) and HAV vaccine (IM), co-administered at Day 1 (Month 0 [M0]); TDV
           (SC) administered at Day 90 (Month 3 [M3])

      This multi-center trial will be conducted in United Kingdom. The overall time to participate
      in this study is 270 days. Participants will have multiple visits to the clinic with a
      6-months follow up after the last study administration, including a final visit at Day 270.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2018</start_date>
  <completion_date type="Actual">July 9, 2019</completion_date>
  <primary_completion_date type="Actual">October 3, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30</measure>
    <time_frame>One month post first vaccination (Day 30)</time_frame>
    <description>Seroprotection is defined as serum anti-HAV antibody levels ≥12.5 mIU/mL, measured by enzyme-linked immunosorbent assay (ELISA). Immunological naivety to HAV/DENV is defined as anti-HAV antibody levels &lt;12.5 mIU/mL and reciprocal neutralizing titers for all 4 dengue serotypes &lt;10. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 30 and Day 120 in Participants HAV/DENV-naive at Baseline</measure>
    <time_frame>One month post first vaccination (Day 30) and one month post second vaccination (Day 120)</time_frame>
    <description>GMTs of neutralizing antibodies were measured by microneutralization test 50% [MNT50] for each of the 4 Dengue Serotypes. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants HAV/DENV-naive at Baseline Who Are Seropositive for Each of the 4 Dengue Serotypes at Day 30 and Day 120</measure>
    <time_frame>One month post first vaccination (Day 30) and one month post second vaccination (Day 120)</time_frame>
    <description>Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of Anti-HAV Antibodies at Day 30 in Participants HAV/DENV-naive at Baseline</measure>
    <time_frame>One month post first vaccination (Day 30)</time_frame>
    <description>GMC of anti-HAV antibodies were measured by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Solicited (Local Injection) Site Adverse Events (AEs) by Severity After Each Vaccination</measure>
    <time_frame>Within 7 days after each vaccination</time_frame>
    <description>Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents daily activity with or without treatment), redness (erythema) (&lt;2.5 cm, mild: 2.5-5 cm, moderate: &gt;5 to &lt;=10 cm, severe: &gt;10 cm) and swelling (edema/induration) (&lt;2.5 cm, mild: 2.5-5 cm, moderate: &gt;5 to &lt;=10 cm, severe: &gt;10 cm ). The percentages were rounded off to the first decimal place.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity After Each Vaccination</measure>
    <time_frame>Within 14 days after each vaccination</time_frame>
    <description>Solicited systemic AEs include fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination. Solicited systemic AEs (headache, asthenia, malaise and myalgia) was graded from 0 to 3 by severity; where 0=None, 1=Mild: No interference with daily activity, 2=Moderate: Interference with daily activity, 3=Severe: Prevents daily activity; A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 14 days after vaccination. Fever was excluded from the overall count as no severity grading was applied for it. The percentages were rounded off to the first decimal place.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Unsolicited Adverse Events (AEs) After Each Vaccination</measure>
    <time_frame>Up to 28 days (Day of Vaccination+27 Subsequent Days) after each vaccination</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>From the first vaccination on Day 1 until the end of the trial (Day 270)</time_frame>
    <description>A SAE is defined as any untoward medical occurrence that: 1) results in death, 2) is life-threatening, 3) requires inpatient hospitalization or prolongation of existing hospitalization, 4) results in persistent or significant disability/incapacity, 5) leads to a congenital anomaly/birth defect in the offspring of the participant or 6) is an medically important event that satisfies any of the following: a) May require intervention to prevent items 1 through 5 above. b) May expose the participant to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Medically Attended AEs (MAAEs)</measure>
    <time_frame>From the first vaccination on Day 1 until the end of the trial (Day 270)</time_frame>
    <description>MAAEs are defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">900</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>HAV Vaccine 1.0 ml + Placebo/ Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDV 0.5 ml + Placebo/ TDV 0.5 ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TDV</intervention_name>
    <description>TDV SC injection</description>
    <arm_group_label>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</arm_group_label>
    <arm_group_label>TDV 0.5 ml + Placebo/ TDV 0.5 ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HAV Vaccine</intervention_name>
    <description>HAV Vaccine IM injection.</description>
    <arm_group_label>HAV Vaccine 1.0 ml + Placebo/ Placebo</arm_group_label>
    <arm_group_label>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TDV Placebo</intervention_name>
    <description>Placebo-matching (normal saline (0.9% NaCl) SC injection.</description>
    <arm_group_label>HAV Vaccine 1.0 ml + Placebo/ Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HAV Vaccine Placebo</intervention_name>
    <description>Placebo-matching (normal saline (0.9% NaCl) IM injection.</description>
    <arm_group_label>TDV 0.5 ml + Placebo/ TDV 0.5 ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The participant is aged 18 to 60 years, inclusive.

          2. Participants who are in good health at the time of entry into the trial as determined
             by medical history, physical examination (including vital signs) and the clinical
             judgment of the Investigator.

          3. The participant signs and dates a written informed consent form and any required
             privacy authorization prior to the initiation of any trial procedures, after the
             nature of the trial has been explained according to local regulatory requirements.

          4. Participants who can comply with trial procedures and are available for the duration
             of follow-up.

        Exclusion Criteria:

          1. Participants with an elevated oral temperature (≥38°C or 100.4°F) within 3 days of the
             intended date of vaccination.

          2. Known hypersensitivity or allergy to any of the vaccine components (including
             excipients of the investigational vaccines or placebo).

          3. Participants with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the Investigator, may interfere with the participant's ability to
             participate in the trial.

          4. Participants with any history of progressive or severe neurologic disorder, seizure
             disorder orneuro-inflammatory disease (eg, Guillain-Barré syndrome).

          5. Participants with history or any illness that, in the opinion of the Investigator,
             might interfere with the results of the trial or pose additional risk to the
             participant due to participation in the trial.

          6. Known or suspected impairment/alteration of immune function, including:

               1. Chronic use of oral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2
                  mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month
                  0) (use of inhaled, intranasal, or topical corticosteroids is allowed).

               2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥ 2
                  mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month
                  0).

               3. Administration of immunoglobulins and/or any blood products within the 3 months
                  prior to Day 1 (Month 0) or planned administration during the trial.

               4. Receipt of immunostimulants within 60 days prior to Day 1 (Month 0).

               5. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy
                  within 6 months prior to Day 1 (Month 0).

               6. Human immunodeficiency virus (HIV) infection or HIV-related disease.

               7. Hepatitis A virus (HAV) infection.

               8. Hepatitis C virus infection.

               9. Genetic immunodeficiency.

          7. Abnormalities of splenic or thymic function.

          8. Participants with a known bleeding diathesis, or any condition that may be associated
             with a prolonged bleeding time.

          9. Participants with any serious chronic or progressive disease according to judgment of
             the Investigator (eg, neoplasm, insulin dependent diabetes, cardiac, renal or hepatic
             disease).

         10. Participants with body mass index (BMI) greater than or equal to 35 kg/m^2 (=weight in
             kg/[height in meters^2]).

         11. Participants participating in any clinical trial with another investigational product
             30 days prior to Day 1 (Month 0) or intent to participate in another clinical trial at
             any time during the conduct of this trial.

         12. Participants who received any other vaccine within 14 days (for inactivated vaccines)
             or 28 days (for live vaccines) prior to enrollment in this trial or who are planning
             to receive any vaccine within 28 days of trial vaccine administration.

         13. Previous HAV vaccination (in a clinical trial or with an approved product).

         14. Participants involved in the trial conduct or their first degree relatives.

         15. Participants with history of substance or alcohol abuse within the past 2 years.

         16. Female participants who are pregnant or breastfeeding.

         17. Females of childbearing potential who are sexually active, and who have not used any
             of the acceptable contraceptive methods for at least 2 months prior to Day 1 (Month
             0).

               1. Of childbearing potential is defined as status post onset of menarche and not
                  meeting any of the following conditions: bilateral tubal ligation (at least 1
                  year previously), bilateral oophorectomy (at least 1 year previously) or
                  hysterectomy

               2. Acceptable birth control methods are defined as one or more of the following:

             i. Hormonal contraceptive (such as oral, injection, transdermal patch, implant,
             cervical ring).

             ii. Barrier method (condom with spermicide or diaphragm with spermicide) each and
             every time during intercourse.

             iii. Intrauterine device (IUD). iv. Monogamous relationship with vasectomized partner
             (partner must have been vasectomized for at least 6 months prior to Day 1 [Month 0]).

             Other contraceptive methods may be considered in agreement with the Sponsor and
             implemented only after approval of a substantial amendment by the regulatory
             authorities and by the appropriate ethics committee.

         18. Females of childbearing potential who are sexually active, and who refuse to use an
             acceptable contraceptive method up to 6 weeks after the last dose of trial vaccine
             (Day 90 [M3]). In addition, they must be advised not to donate ova during this period.

         19. Any positive or indeterminate pregnancy test.

         20. Previous and planned vaccination (during the trial conduct) against any flaviviruses
             including dengue, yellow fever (YF), Japanese Encephalitis (JE) viruses or tick-borne
             encephalitis.

         21. Previous participation in any clinical trial of a dengue or other flavivirus (eg, West
             Nile [WN] virus) candidate vaccine, except for participants who received placebo in
             those trials.

         22. Participants with a current or previous infection with a flavivirus such as dengue,
             Zika, YF, JE, WN fever, tick-borne encephalitis or Murray Valley encephalitis and
             participants with a history of prolonged (≥1 year) habitation in a dengue endemic
             area.

         23. Participants with contraindications, warnings and/or precautions to vaccination with
             the HAV vaccine as specified within the product information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synexus - Midlands</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Lancashire</name>
      <address>
        <city>Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Merseyside</name>
      <address>
        <city>Waterloo</city>
        <state>Liverpool</state>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Yorkshire</state>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF15 9SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Scotland</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North East Clinical Research Centre, Hexham General Hospital</name>
      <address>
        <city>Hexham</city>
        <zip>NE46 1QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Thames Valley</name>
      <address>
        <city>Reading</city>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Tees Clinical Research Centre, Middlefield Centre, University Hospital of North Tees</name>
      <address>
        <city>Stockton-on-Tees</city>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <results_first_submitted>June 24, 2020</results_first_submitted>
  <results_first_submitted_qc>June 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2020</results_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03525119/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT03525119/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 10 investigative sites in United Kingdom from 16-May-2018 to 09-Jul-2019.</recruitment_details>
      <pre_assignment_details>Healthy participants were randomized in 1:1:1 ratio in 3 parallel groups: Group 1 received 1 dose of Hepatitis A Virus (HAV) vaccine and Tetravalent Dengue Vaccine Candidate (TDV) placebo matching injection, Group 2 received 2 doses of TDV and HAV vaccine placebo matching injection and Group 3 received 1 dose of HAV vaccine and 2 doses of TDV.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HAV Vaccine 1.0 ml + Placebo/ Placebo</title>
          <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
        </group>
        <group group_id="P2">
          <title>TDV 0.5 ml + Placebo/ TDV 0.5 ml</title>
          <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
        </group>
        <group group_id="P3">
          <title>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</title>
          <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="300"/>
                <participants group_id="P3" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="300"/>
                <participants group_id="P3" count="298"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="261"/>
                <participants group_id="P3" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Set included all participants enrolled and randomized in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>HAV Vaccine 1.0 ml + Placebo/ Placebo</title>
          <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
        </group>
        <group group_id="B2">
          <title>TDV 0.5 ml + Placebo/ TDV 0.5 ml</title>
          <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
        </group>
        <group group_id="B3">
          <title>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</title>
          <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="300"/>
            <count group_id="B2" value="300"/>
            <count group_id="B3" value="300"/>
            <count group_id="B4" value="900"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="300"/>
                    <count group_id="B2" value="300"/>
                    <count group_id="B3" value="300"/>
                    <count group_id="B4" value="900"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.7" spread="12.03"/>
                    <measurement group_id="B2" value="36.0" spread="11.88"/>
                    <measurement group_id="B3" value="35.5" spread="11.94"/>
                    <measurement group_id="B4" value="35.4" spread="11.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="300"/>
                    <count group_id="B2" value="300"/>
                    <count group_id="B3" value="300"/>
                    <count group_id="B4" value="900"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="317"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="210"/>
                    <measurement group_id="B4" value="583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="300"/>
                    <count group_id="B2" value="300"/>
                    <count group_id="B3" value="300"/>
                    <count group_id="B4" value="900"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="290"/>
                    <measurement group_id="B2" value="293"/>
                    <measurement group_id="B3" value="296"/>
                    <measurement group_id="B4" value="879"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="300"/>
                    <count group_id="B2" value="300"/>
                    <count group_id="B3" value="300"/>
                    <count group_id="B4" value="900"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="279"/>
                    <measurement group_id="B4" value="840"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="300"/>
                    <count group_id="B2" value="300"/>
                    <count group_id="B3" value="300"/>
                    <count group_id="B4" value="900"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="300"/>
                    <measurement group_id="B4" value="900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Number analyzed is the number of participants with data available at Baseline.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="299"/>
                    <count group_id="B2" value="300"/>
                    <count group_id="B3" value="297"/>
                    <count group_id="B4" value="896"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173.80" spread="9.299"/>
                    <measurement group_id="B2" value="172.12" spread="9.163"/>
                    <measurement group_id="B3" value="173.00" spread="9.110"/>
                    <measurement group_id="B4" value="172.97" spread="9.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Number analyzed is the number of participants with data available at Baseline.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="299"/>
                    <count group_id="B2" value="300"/>
                    <count group_id="B3" value="297"/>
                    <count group_id="B4" value="896"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.24" spread="15.547"/>
                    <measurement group_id="B2" value="78.18" spread="15.570"/>
                    <measurement group_id="B3" value="78.92" spread="15.243"/>
                    <measurement group_id="B4" value="78.78" spread="15.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI=Weight/Height.</description>
          <population>Number analyzed is the number of participants with data available at Baseline.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="299"/>
                    <count group_id="B2" value="300"/>
                    <count group_id="B3" value="297"/>
                    <count group_id="B4" value="896"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.16" spread="4.256"/>
                    <measurement group_id="B2" value="26.31" spread="4.354"/>
                    <measurement group_id="B3" value="26.29" spread="4.283"/>
                    <measurement group_id="B4" value="26.25" spread="4.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Seroprotection Against HAV</title>
          <description>Seroprotection was defined as serum anti-HAV antibody levels ≥12.5 mIU/mL, measured by Enzyme-Linked Immunosorbent Assay (ELISA).</description>
          <population>Number analyzed is the number of participants from Immunogenicity Subset, with data available for analyses at Baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="118"/>
                    <count group_id="B2" value="121"/>
                    <count group_id="B3" value="122"/>
                    <count group_id="B4" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Seropositivity Status for Dengue</title>
          <description>Seropositivity defined as a reciprocal neutralizing titer &gt;=10 for at least 1 dengue serotype. Seronegativity was defined as having a reciprocal neutralizing titer &lt;10 for all dengue serotypes. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.</description>
          <population>Number analyzed is the number of participants from Immunogenicity Subset, with data available for analyses at Baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="118"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Seropositive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Seronegative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Seropositivity Rate for Each Dengue Serotype</title>
          <description>Seropositivity rate, defined as the percentage of participants seropositive for the given dengue serotype, derived from the titers of dengue-neutralizing antibodies. Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.</description>
          <population>Number analyzed is the number of participants from Immunogenicity Subset, with data available for analyses at Baseline. Participants are repeated across categories as seropositivity for more than serotype is reported.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>DENV-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="118"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="118"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="118"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV-4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="118"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="120"/>
                    <count group_id="B4" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30</title>
        <description>Seroprotection is defined as serum anti-HAV antibody levels ≥12.5 mIU/mL, measured by enzyme-linked immunosorbent assay (ELISA). Immunological naivety to HAV/DENV is defined as anti-HAV antibody levels &lt;12.5 mIU/mL and reciprocal neutralizing titers for all 4 dengue serotypes &lt;10. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.</description>
        <time_frame>One month post first vaccination (Day 30)</time_frame>
        <population>HAV PPS: All HAV &amp; DENV-naïve participants in the immunogenicity subset who received at least 1 dose of trial vaccine, with available Day 1 and Day 30 HAV immunogenicity measurements, and who have no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Vaccine 1.0 ml + Placebo/ Placebo</title>
            <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O2">
            <title>TDV 0.5 ml + Placebo/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30</title>
          <description>Seroprotection is defined as serum anti-HAV antibody levels ≥12.5 mIU/mL, measured by enzyme-linked immunosorbent assay (ELISA). Immunological naivety to HAV/DENV is defined as anti-HAV antibody levels &lt;12.5 mIU/mL and reciprocal neutralizing titers for all 4 dengue serotypes &lt;10. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.</description>
          <population>HAV PPS: All HAV &amp; DENV-naïve participants in the immunogenicity subset who received at least 1 dose of trial vaccine, with available Day 1 and Day 30 HAV immunogenicity measurements, and who have no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="89.8" upper_limit="99.6"/>
                    <measurement group_id="O2" value="9.1" lower_limit="3.4" upper_limit="18.7"/>
                    <measurement group_id="O3" value="98.7" lower_limit="93.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>As per predefined criteria in protocol the non-inferiority was established only between group 1 and group 3. Non-inferiority of HAV+TDV to HAV was established if the upper bound of the 95% CI was less than 10%.</non_inferiority_desc>
            <param_type>Seroprotection Rate Difference</param_type>
            <param_value>-1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.91</ci_lower_limit>
            <ci_upper_limit>4.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 30 and Day 120 in Participants HAV/DENV-naive at Baseline</title>
        <description>GMTs of neutralizing antibodies were measured by microneutralization test 50% [MNT50] for each of the 4 Dengue Serotypes. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.</description>
        <time_frame>One month post first vaccination (Day 30) and one month post second vaccination (Day 120)</time_frame>
        <population>TDV PPS: All HAV &amp; DENV-naïve participants in the immunogenicity subset who received at least 1 dose of trial vaccine, with available Day 1 and at least 1 post-dose immunogenicity measurements, and who have no major protocol violations. Number analyzed are participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Vaccine 1.0 ml + Placebo/ Placebo</title>
            <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O2">
            <title>TDV 0.5 ml + Placebo/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 30 and Day 120 in Participants HAV/DENV-naive at Baseline</title>
          <description>GMTs of neutralizing antibodies were measured by microneutralization test 50% [MNT50] for each of the 4 Dengue Serotypes. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.</description>
          <population>TDV PPS: All HAV &amp; DENV-naïve participants in the immunogenicity subset who received at least 1 dose of trial vaccine, with available Day 1 and at least 1 post-dose immunogenicity measurements, and who have no major protocol violations. Number analyzed are participants with data available at the given timepoint.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DENV 1, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="NA" upper_limit="NA">Lower and upper limits of CI could not be evaluated as titers were below the lower limit of detection (LLOD).</measurement>
                    <measurement group_id="O2" value="108.2" lower_limit="69.2" upper_limit="169.1"/>
                    <measurement group_id="O3" value="152.5" lower_limit="104.4" upper_limit="222.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 2, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="5.1" upper_limit="7.1"/>
                    <measurement group_id="O2" value="2897.9" lower_limit="1469.2" upper_limit="5715.6"/>
                    <measurement group_id="O3" value="3960.0" lower_limit="2310.7" upper_limit="6786.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 3, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.7" upper_limit="5.8"/>
                    <measurement group_id="O2" value="95.4" lower_limit="59.5" upper_limit="153.2"/>
                    <measurement group_id="O3" value="140.5" lower_limit="96.8" upper_limit="203.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 4, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="NA" upper_limit="NA">Lower and upper limits of CI could not be evaluated as titers were below the LLOD.</measurement>
                    <measurement group_id="O2" value="74.3" lower_limit="49.0" upper_limit="112.9"/>
                    <measurement group_id="O3" value="142.1" lower_limit="90.5" upper_limit="223.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 1, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="NA" upper_limit="NA">Lower and upper limits of CI could not be evaluated as titers were below the LLOD.</measurement>
                    <measurement group_id="O2" value="171.3" lower_limit="104.5" upper_limit="281.0"/>
                    <measurement group_id="O3" value="173.7" lower_limit="120.1" upper_limit="251.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 2, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="4.9" upper_limit="6.7"/>
                    <measurement group_id="O2" value="2064.1" lower_limit="1459.7" upper_limit="2918.9"/>
                    <measurement group_id="O3" value="1764.3" lower_limit="1238.6" upper_limit="2513.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 3, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="NA" upper_limit="NA">Lower and upper limits of CI could not be evaluated as titers were below the LLOD.</measurement>
                    <measurement group_id="O2" value="83.8" lower_limit="59.0" upper_limit="119.0"/>
                    <measurement group_id="O3" value="92.6" lower_limit="71.3" upper_limit="120.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 4, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="NA" upper_limit="NA">Lower and upper limits of CI could not be evaluated as titers were below the LLOD.</measurement>
                    <measurement group_id="O2" value="56.1" lower_limit="41.0" upper_limit="76.7"/>
                    <measurement group_id="O3" value="81.4" lower_limit="59.2" upper_limit="111.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants HAV/DENV-naive at Baseline Who Are Seropositive for Each of the 4 Dengue Serotypes at Day 30 and Day 120</title>
        <description>Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.</description>
        <time_frame>One month post first vaccination (Day 30) and one month post second vaccination (Day 120)</time_frame>
        <population>TDV PPS: All HAV &amp; DENV-naïve participants in the immunogenicity subset who received at least 1 dose of trial vaccine, with available Day 1 and at least 1 post-dose immunogenicity measurements, and who have no major protocol violations. Number analyzed are participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Vaccine 1.0 ml + Placebo/ Placebo</title>
            <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O2">
            <title>TDV 0.5 ml + Placebo/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants HAV/DENV-naive at Baseline Who Are Seropositive for Each of the 4 Dengue Serotypes at Day 30 and Day 120</title>
          <description>Seropositivity is defined as a reciprocal neutralizing titer ≥10. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.</description>
          <population>TDV PPS: All HAV &amp; DENV-naïve participants in the immunogenicity subset who received at least 1 dose of trial vaccine, with available Day 1 and at least 1 post-dose immunogenicity measurements, and who have no major protocol violations. Number analyzed are participants with data available at the given timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DENV 1, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="88.3" lower_limit="77.4" upper_limit="95.2"/>
                    <measurement group_id="O3" value="95.4" lower_limit="87.1" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 2, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="2.7" upper_limit="18.1"/>
                    <measurement group_id="O2" value="91.7" lower_limit="81.6" upper_limit="97.2"/>
                    <measurement group_id="O3" value="96.9" lower_limit="89.3" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 3, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="8.8"/>
                    <measurement group_id="O2" value="85.0" lower_limit="73.4" upper_limit="92.9"/>
                    <measurement group_id="O3" value="95.4" lower_limit="87.1" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 4, Day 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="5.9"/>
                    <measurement group_id="O2" value="86.7" lower_limit="75.4" upper_limit="94.1"/>
                    <measurement group_id="O3" value="90.8" lower_limit="81.0" upper_limit="96.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 1, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.5" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="94.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 2, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="1.3" upper_limit="16.5"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.5" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="94.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 3, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="92.7" lower_limit="82.4" upper_limit="98.0"/>
                    <measurement group_id="O3" value="98.4" lower_limit="91.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENV 4, Day 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="96.4" lower_limit="87.5" upper_limit="99.6"/>
                    <measurement group_id="O3" value="96.8" lower_limit="88.8" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of Anti-HAV Antibodies at Day 30 in Participants HAV/DENV-naive at Baseline</title>
        <description>GMC of anti-HAV antibodies were measured by ELISA.</description>
        <time_frame>One month post first vaccination (Day 30)</time_frame>
        <population>HAV PPS: All HAV &amp; DENV-naïve participants in the immunogenicity subset who received at least 1 dose of trial vaccine, with available Day 1 and Day 30 HAV immunogenicity measurements, and who have no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Vaccine 1.0 ml + Placebo/ Placebo</title>
            <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O2">
            <title>TDV 0.5 ml + Placebo/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of Anti-HAV Antibodies at Day 30 in Participants HAV/DENV-naive at Baseline</title>
          <description>GMC of anti-HAV antibodies were measured by ELISA.</description>
          <population>HAV PPS: All HAV &amp; DENV-naïve participants in the immunogenicity subset who received at least 1 dose of trial vaccine, with available Day 1 and Day 30 HAV immunogenicity measurements, and who have no major protocol violations.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.1" lower_limit="62.9" upper_limit="107.1"/>
                    <measurement group_id="O2" value="6.7" lower_limit="6.4" upper_limit="7.2"/>
                    <measurement group_id="O3" value="93.0" lower_limit="76.1" upper_limit="113.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Solicited (Local Injection) Site Adverse Events (AEs) by Severity After Each Vaccination</title>
        <description>Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents daily activity with or without treatment), redness (erythema) (&lt;2.5 cm, mild: 2.5-5 cm, moderate: &gt;5 to &lt;=10 cm, severe: &gt;10 cm) and swelling (edema/induration) (&lt;2.5 cm, mild: 2.5-5 cm, moderate: &gt;5 to &lt;=10 cm, severe: &gt;10 cm ). The percentages were rounded off to the first decimal place.</description>
        <time_frame>Within 7 days after each vaccination</time_frame>
        <population>Safety Set included all participants who received at least 1 dose of trial vaccine. Number analyzed is the number of participants with data available for the specific category. Only categories for which there was at least 1 participant are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Vaccine 1.0 ml + Placebo/ Placebo</title>
            <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O2">
            <title>TDV 0.5 ml + Placebo/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited (Local Injection) Site Adverse Events (AEs) by Severity After Each Vaccination</title>
          <description>Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents daily activity with or without treatment), redness (erythema) (&lt;2.5 cm, mild: 2.5-5 cm, moderate: &gt;5 to &lt;=10 cm, severe: &gt;10 cm) and swelling (edema/induration) (&lt;2.5 cm, mild: 2.5-5 cm, moderate: &gt;5 to &lt;=10 cm, severe: &gt;10 cm ). The percentages were rounded off to the first decimal place.</description>
          <population>Safety Set included all participants who received at least 1 dose of trial vaccine. Number analyzed is the number of participants with data available for the specific category. Only categories for which there was at least 1 participant are reported.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After First Vaccination IM,Any Local AEs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="15.4"/>
                    <measurement group_id="O3" value="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, IM, Pain-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6"/>
                    <measurement group_id="O2" value="14.4"/>
                    <measurement group_id="O3" value="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, IM, Pain-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="13.0"/>
                    <measurement group_id="O3" value="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, IM, Pain-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, IM, Pain-Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, IM, Erythema-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, IM, Erythema-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, IM, Erythema-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, IM, Swelling-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="285"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, IM, Swelling-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="285"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, SC,Any Local AEs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="47.3"/>
                    <measurement group_id="O3" value="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination SC, Pain-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2"/>
                    <measurement group_id="O2" value="40.4"/>
                    <measurement group_id="O3" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination SC, Pain-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="35.6"/>
                    <measurement group_id="O3" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, SC, Pain-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="4.8"/>
                    <measurement group_id="O3" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, SC, Erythema-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="16.8"/>
                    <measurement group_id="O3" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, SC, Erythema-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="15.8"/>
                    <measurement group_id="O3" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, SC, Erythema-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, SC, Swelling-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, SC, Swelling-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, SC,Any Local AEs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="264"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="37.9"/>
                    <measurement group_id="O3" value="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, SC,Pain-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="34.7"/>
                    <measurement group_id="O3" value="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, SC,Pain-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="30.9"/>
                    <measurement group_id="O3" value="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, SC,Pain-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, SC,Pain-Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, SC,Erythema-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="12.9"/>
                    <measurement group_id="O3" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, SC,Erythema-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, SC,Erythema-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, SC,Swelling-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, SC,Swelling-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, SC,Swelling-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity After Each Vaccination</title>
        <description>Solicited systemic AEs include fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination. Solicited systemic AEs (headache, asthenia, malaise and myalgia) was graded from 0 to 3 by severity; where 0=None, 1=Mild: No interference with daily activity, 2=Moderate: Interference with daily activity, 3=Severe: Prevents daily activity; A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 14 days after vaccination. Fever was excluded from the overall count as no severity grading was applied for it. The percentages were rounded off to the first decimal place.</description>
        <time_frame>Within 14 days after each vaccination</time_frame>
        <population>Safety Set included all participants who received at least 1 dose of trial vaccine. Number analyzed is the number of participants with data available for the specific category. Only categories for which there was at least 1 participant are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Vaccine 1.0 ml + Placebo/ Placebo</title>
            <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O2">
            <title>TDV 0.5 ml + Placebo/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Severity After Each Vaccination</title>
          <description>Solicited systemic AEs include fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination. Solicited systemic AEs (headache, asthenia, malaise and myalgia) was graded from 0 to 3 by severity; where 0=None, 1=Mild: No interference with daily activity, 2=Moderate: Interference with daily activity, 3=Severe: Prevents daily activity; A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 14 days after vaccination. Fever was excluded from the overall count as no severity grading was applied for it. The percentages were rounded off to the first decimal place.</description>
          <population>Safety Set included all participants who received at least 1 dose of trial vaccine. Number analyzed is the number of participants with data available for the specific category. Only categories for which there was at least 1 participant are reported.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After First Vaccination, Any Systemic AEs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4"/>
                    <measurement group_id="O2" value="44.2"/>
                    <measurement group_id="O3" value="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Headache-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="32.5"/>
                    <measurement group_id="O3" value="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Headache-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="22.3"/>
                    <measurement group_id="O3" value="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Headache-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="8.2"/>
                    <measurement group_id="O3" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Headache-Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Asthenia-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0"/>
                    <measurement group_id="O2" value="15.8"/>
                    <measurement group_id="O3" value="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Asthenia-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Asthenia-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="5.5"/>
                    <measurement group_id="O3" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Asthenia-Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Malaise-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="21.2"/>
                    <measurement group_id="O3" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Malaise-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="13.7"/>
                    <measurement group_id="O3" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Malaise-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Malaise-Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Myalgia-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4"/>
                    <measurement group_id="O2" value="22.9"/>
                    <measurement group_id="O3" value="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Myalgia-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="16.4"/>
                    <measurement group_id="O3" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Myalgia-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="6.2"/>
                    <measurement group_id="O3" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Myalgia-Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Fever-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="284"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Fever-38.0-&lt;38.5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="284"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Fever-38.5-&lt;39.0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="284"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Fever-39.0-&lt;39.5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="284"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After First Vaccination, Fever-≥41.0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="289"/>
                    <count group_id="O2" value="292"/>
                    <count group_id="O3" value="284"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Any Systemic AEs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6"/>
                    <measurement group_id="O2" value="30.2"/>
                    <measurement group_id="O3" value="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Headache-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7"/>
                    <measurement group_id="O2" value="17.2"/>
                    <measurement group_id="O3" value="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Headache-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="12.6"/>
                    <measurement group_id="O3" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Headache-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Headache-Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Asthenia-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="7.6"/>
                    <measurement group_id="O3" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Asthenia-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Asthenia-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Asthenia-Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Malaise-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="14.9"/>
                    <measurement group_id="O3" value="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Malaise-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="9.9"/>
                    <measurement group_id="O3" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Malaise-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="3.8"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Malaise-Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Myalgia-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="15.6"/>
                    <measurement group_id="O3" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Myalgia-Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="13.0"/>
                    <measurement group_id="O3" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Myalgia-Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Myalgia-Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Fever-Any</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Fever-38.0-&lt;38.5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Fever-38.5-&lt;39.0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination, Fever-39.5-&lt;40.0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Unsolicited Adverse Events (AEs) After Each Vaccination</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.</description>
        <time_frame>Up to 28 days (Day of Vaccination+27 Subsequent Days) after each vaccination</time_frame>
        <population>Safety Set included all participants who received at least 1 dose of trial vaccine. Number analyzed is the number of participants with data available for the specific category.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Vaccine 1.0 ml + Placebo/ Placebo</title>
            <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O2">
            <title>TDV 0.5 ml + Placebo/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Unsolicited Adverse Events (AEs) After Each Vaccination</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.</description>
          <population>Safety Set included all participants who received at least 1 dose of trial vaccine. Number analyzed is the number of participants with data available for the specific category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After First Vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="300"/>
                    <count group_id="O3" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="17.0"/>
                    <measurement group_id="O3" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Second Vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="270"/>
                    <count group_id="O2" value="271"/>
                    <count group_id="O3" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serious Adverse Events (SAEs)</title>
        <description>A SAE is defined as any untoward medical occurrence that: 1) results in death, 2) is life-threatening, 3) requires inpatient hospitalization or prolongation of existing hospitalization, 4) results in persistent or significant disability/incapacity, 5) leads to a congenital anomaly/birth defect in the offspring of the participant or 6) is an medically important event that satisfies any of the following: a) May require intervention to prevent items 1 through 5 above. b) May expose the participant to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization.</description>
        <time_frame>From the first vaccination on Day 1 until the end of the trial (Day 270)</time_frame>
        <population>Safety Set included all participants who received at least 1 dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Vaccine 1.0 ml + Placebo/ Placebo</title>
            <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O2">
            <title>TDV 0.5 ml + Placebo/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Adverse Events (SAEs)</title>
          <description>A SAE is defined as any untoward medical occurrence that: 1) results in death, 2) is life-threatening, 3) requires inpatient hospitalization or prolongation of existing hospitalization, 4) results in persistent or significant disability/incapacity, 5) leads to a congenital anomaly/birth defect in the offspring of the participant or 6) is an medically important event that satisfies any of the following: a) May require intervention to prevent items 1 through 5 above. b) May expose the participant to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization.</description>
          <population>Safety Set included all participants who received at least 1 dose of trial vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Medically Attended AEs (MAAEs)</title>
        <description>MAAEs are defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.</description>
        <time_frame>From the first vaccination on Day 1 until the end of the trial (Day 270)</time_frame>
        <population>Safety Set included all participants who received at least 1 dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Vaccine 1.0 ml + Placebo/ Placebo</title>
            <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O2">
            <title>TDV 0.5 ml + Placebo/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
          <group group_id="O3">
            <title>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</title>
            <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Medically Attended AEs (MAAEs)</title>
          <description>MAAEs are defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.</description>
          <population>Safety Set included all participants who received at least 1 dose of trial vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="21.0"/>
                    <measurement group_id="O3" value="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality and Serious adverse events: From the first vaccination on Day 1 until the end of the trial (Day 270); Other adverse events: Up to 28 days (Day of vaccination+27 subsequent days) after each vaccination.</time_frame>
      <desc>Safety Set included all participants who received at least 1 dose of trial vaccine.</desc>
      <group_list>
        <group group_id="E1">
          <title>HAV Vaccine 1.0 ml + Placebo/ Placebo</title>
          <description>HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).</description>
        </group>
        <group group_id="E2">
          <title>TDV 0.5 ml + Placebo/ TDV 0.5 ml</title>
          <description>TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
        </group>
        <group group_id="E3">
          <title>TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml</title>
          <description>TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

